A survey of UK general practitioners about depression, antidepressants and withdrawal: implementing the 2019 Public Health England report
- PMID: 32922735
- PMCID: PMC7457636
- DOI: 10.1177/2045125320950124
A survey of UK general practitioners about depression, antidepressants and withdrawal: implementing the 2019 Public Health England report
Abstract
Background: In 2019, a literature review indicated that more than half of people who try to come off antidepressants experience withdrawal effects. Both the National Institute of Health and Care Excellence and the Royal College of Psychiatrists updated their positions in line with that review, and Public Health England published a 152-page report called Dependence and withdrawal associated with some prescribed medicines: an evidence review. The report made several recommendations relevant to general practice.
Method: In order to facilitate implementation of these recommendations, an online survey was designed to explore United Kingdom general practitioner (GP) experiences, opinions, knowledge and needs in relation to depression, ADs and withdrawal. A total of 66 GPs had completed the survey when COVID-19 occurred.
Results: In keeping with previous findings, this small sample of GPs had a predominantly psycho-social perspective on the causes of, and treatments for, depression. They broadly considered ADs effective for moderate/severe depression and ineffective for minimal/mild depression, for which they preferred psychological therapies and social prescribing. There was a marked lack of consistency in GPs' knowledge about the incidence and duration of withdrawal effects. Only a minority (29%) felt their knowledge about withdrawal was 'adequate' and fewer (17%) believed this about their 'Ability to distinguish between withdrawal effects and return of the original problem (e.g. depression)'. Two-thirds (68%) would like more training on these matters.
Conclusion: It is hoped that even this small sample will be helpful when designing, and seeking funding for, GP training programmes, and when implementing the PHE recommendations for support services, based in the primary care system, for the millions of people contemplating or initiating withdrawal from ADs every year in the UK.
Keywords: Antidepressants; Depression; General Practitioners; Primary Care; Training; Withdrawal.
© The Author(s), 2020.
Conflict of interest statement
Conflict of interest statement: The authors declare that there is no conflict of interest.
Similar articles
-
REDUCE (Reviewing long-term antidepressant use by careful monitoring in everyday practice) internet and telephone support to people coming off long-term antidepressants: protocol for a randomised controlled trial.Trials. 2020 May 24;21(1):419. doi: 10.1186/s13063-020-04338-7. Trials. 2020. PMID: 32448374 Free PMC article.
-
Policies and strategies to retain and support the return of experienced GPs in direct patient care: the ReGROUP mixed-methods study.Southampton (UK): NIHR Journals Library; 2019 Apr. Southampton (UK): NIHR Journals Library; 2019 Apr. PMID: 30973692 Free Books & Documents. Review.
-
Implementation of evidence-based knowledge in general practice.Dan Med J. 2017 Dec;64(12):B5405. Dan Med J. 2017. PMID: 29206099
-
Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT.Health Technol Assess. 2021 Nov;25(69):1-62. doi: 10.3310/hta25690. Health Technol Assess. 2021. PMID: 34842135 Clinical Trial.
-
Optimal primary care management of clinical osteoarthritis and joint pain in older people: a mixed-methods programme of systematic reviews, observational and qualitative studies, and randomised controlled trials.Southampton (UK): NIHR Journals Library; 2018 Jul. Southampton (UK): NIHR Journals Library; 2018 Jul. PMID: 30048076 Free Books & Documents. Review.
Cited by
-
Outcomes of hyperbolic tapering of antidepressants.Ther Adv Psychopharmacol. 2023 May 9;13:20451253231171518. doi: 10.1177/20451253231171518. eCollection 2023. Ther Adv Psychopharmacol. 2023. PMID: 37200818 Free PMC article.
-
Factors Associated with Psychotropic Medications Literacy among Community Pharmacists.Medicina (Kaunas). 2023 Mar 20;59(3):618. doi: 10.3390/medicina59030618. Medicina (Kaunas). 2023. PMID: 36984619 Free PMC article.
-
The serotonin theory of depression and why we use antidepressants.Br J Gen Pract. 2022 Oct 27;72(724):536-537. doi: 10.3399/bjgp22X721109. Print 2022 Nov. Br J Gen Pract. 2022. PMID: 36302678 Free PMC article. No abstract available.
-
The serotonin theory of depression: a systematic umbrella review of the evidence.Mol Psychiatry. 2023 Aug;28(8):3243-3256. doi: 10.1038/s41380-022-01661-0. Epub 2022 Jul 20. Mol Psychiatry. 2023. PMID: 35854107 Free PMC article.
-
A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases.Pharmaceuticals (Basel). 2022 May 1;15(5):565. doi: 10.3390/ph15050565. Pharmaceuticals (Basel). 2022. PMID: 35631391 Free PMC article.
References
-
- Taylor S, Annand F, Burkinshaw P, et al. Dependence and withdrawal associated with some prescribed medicines: An evidence review. London: Public Health England, 2019.
-
- Pratt L, Brody D, Gu Q. Antidepressant use among persons aged 12 and over: United States, 2011–2014. Data Brief No. 283. Washington DC: National Centre for Health Statistics, 2017. - PubMed
-
- Organisation for Economic Cooperation and Development (OECD). Antidepressant drugs consumption, 2000 and 2015 (or nearest year) in Pharmaceutical sector. Paris: OECD, 2017. 10.1787/health_glance-2017-graph181-en (accessed 10 June 2020). - DOI
-
- Khan A, Khan S, Brown W. Are placebo controls necessary to test new antidepressants and anxiolytics? Int J Neuropsychopharmacol 2002; 5: 193–197. - PubMed
LinkOut - more resources
Full Text Sources
